Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Neurocrine Biosciences Inc has a consensus price target of $160.28 based on the ratings of 25 analysts. The high is $219 issued by Oppenheimer on August 2, 2024. The low is $115 issued by BMO Capital on May 6, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, RBC Capital, and Guggenheim on May 6, 2025, respectively. With an average price target of $154.67 between Piper Sandler, RBC Capital, and Guggenheim, there's an implied 28.29% upside for Neurocrine Biosciences Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/06/2025 | Buy Now | 27.74% | Piper Sandler | David Amsellem75% | $160 → $154 | Reiterates | Overweight → Overweight | Get Alert |
05/06/2025 | Buy Now | 20.27% | RBC Capital | Brian Abrahams31% | $137 → $145 | Maintains | Outperform | Get Alert |
05/06/2025 | Buy Now | 36.86% | Guggenheim | Yatin Suneja47% | $155 → $165 | Maintains | Buy | Get Alert |
05/06/2025 | Buy Now | -4.61% | BMO Capital | Evan Seigerman62% | $96 → $115 | Maintains | Market Perform | Get Alert |
05/06/2025 | Buy Now | 26.08% | UBS | Ashwani Verma51% | $137 → $152 | Maintains | Buy | Get Alert |
05/06/2025 | Buy Now | 32.71% | Canaccord Genuity | Sumant Kulkarni34% | $158 → $160 | Maintains | Buy | Get Alert |
05/06/2025 | Buy Now | 15.3% | Needham | Ami Fadia53% | $138 → $139 | Maintains | Buy | Get Alert |
04/28/2025 | Buy Now | 31.06% | Canaccord Genuity | Sumant Kulkarni34% | $163 → $158 | Maintains | Buy | Get Alert |
04/24/2025 | Buy Now | 53.45% | Evercore ISI Group | Cory Kasimov68% | $190 → $185 | Maintains | Outperform | Get Alert |
04/22/2025 | Buy Now | 39.35% | HC Wainwright & Co. | Andrew Fein54% | $185 → $168 | Maintains | Buy | Get Alert |
04/15/2025 | Buy Now | 14.47% | Needham | Ami Fadia53% | → $138 | Upgrade | Hold → Buy | Get Alert |
04/14/2025 | Buy Now | 13.64% | RBC Capital | Brian Abrahams31% | $138 → $137 | Upgrade | Sector Perform → Outperform | Get Alert |
04/04/2025 | Buy Now | 13.64% | UBS | Ashwani Verma51% | $154 → $137 | Maintains | Buy | Get Alert |
03/26/2025 | Buy Now | 52.62% | JP Morgan | Anupam Rama55% | $183 → $184 | Maintains | Overweight | Get Alert |
03/07/2025 | Buy Now | 24.42% | Morgan Stanley | Jeffrey Hung53% | $185 → $150 | Assumes | → Overweight | Get Alert |
02/24/2025 | Buy Now | 53.45% | HC Wainwright & Co. | Andrew Fein54% | $185 → $185 | Reiterates | Buy → Buy | Get Alert |
02/21/2025 | Buy Now | 53.45% | HC Wainwright & Co. | Andrew Fein54% | $185 → $185 | Reiterates | Buy → Buy | Get Alert |
02/10/2025 | Buy Now | 35.2% | Guggenheim | Yatin Suneja47% | $165 → $163 | Maintains | Buy | Get Alert |
02/10/2025 | Buy Now | 53.45% | HC Wainwright & Co. | Andrew Fein54% | $190 → $185 | Maintains | Buy | Get Alert |
02/07/2025 | Buy Now | 22.76% | RBC Capital | Brian Abrahams31% | $154 → $148 | Maintains | Sector Perform | Get Alert |
02/07/2025 | Buy Now | 21.93% | Wedbush | Laura Chico36% | $157 → $147 | Maintains | Outperform | Get Alert |
02/07/2025 | Buy Now | 35.2% | Canaccord Genuity | Sumant Kulkarni34% | $172 → $163 | Maintains | Buy | Get Alert |
02/07/2025 | Buy Now | 53.45% | HC Wainwright & Co. | Andrew Fein54% | $190 → $185 | Maintains | Buy | Get Alert |
02/07/2025 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | Hold → Hold | Get Alert |
02/07/2025 | Buy Now | 48.47% | B of A Securities | Tazeen Ahmad73% | $184 → $179 | Maintains | Buy | Get Alert |
02/04/2025 | Buy Now | 53.45% | Morgan Stanley | Jeffrey Hung53% | $170 → $185 | Maintains | Overweight | Get Alert |
01/30/2025 | Buy Now | 45.99% | UBS | Ashwani Verma51% | $162 → $176 | Maintains | Buy | Get Alert |
01/08/2025 | Buy Now | 34.37% | UBS | Ashwani Verma51% | $142 → $162 | Maintains | Buy | Get Alert |
12/23/2024 | Buy Now | 32.71% | Piper Sandler | David Amsellem75% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
12/23/2024 | Buy Now | 36.86% | Barclays | Carter Gould53% | $160 → $165 | Maintains | Overweight | Get Alert |
12/20/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | Hold → Hold | Get Alert |
12/16/2024 | Buy Now | 22.76% | Wedbush | Laura Chico36% | $148 → $148 | Reiterates | Outperform → Outperform | Get Alert |
12/16/2024 | Buy Now | 57.6% | HC Wainwright & Co. | Andrew Fein54% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
11/11/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
11/01/2024 | Buy Now | 57.6% | HC Wainwright & Co. | Andrew Fein54% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
10/31/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
10/30/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
10/29/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
10/17/2024 | Buy Now | -5.44% | BMO Capital | Evan Seigerman62% | $128 → $114 | Maintains | Market Perform | Get Alert |
10/10/2024 | Buy Now | 28.57% | Raymond James | Danielle Brill25% | → $155 | Reinstates | → Outperform | Get Alert |
10/08/2024 | Buy Now | 10.32% | RBC Capital | Brian Abrahams31% | $133 → $133 | Reiterates | Sector Perform → Sector Perform | Get Alert |
10/04/2024 | Buy Now | 10.32% | RBC Capital | Brian Abrahams31% | $136 → $133 | Maintains | Sector Perform | Get Alert |
09/16/2024 | Buy Now | 28.57% | Cantor Fitzgerald | Charles Duncan69% | $155 → $155 | Reiterates | Overweight → Overweight | Get Alert |
09/09/2024 | Buy Now | 32.71% | Barclays | Carter Gould53% | $180 → $160 | Maintains | Overweight | Get Alert |
08/29/2024 | Buy Now | 28.57% | Cantor Fitzgerald | Charles Duncan69% | $170 → $155 | Maintains | Overweight | Get Alert |
08/29/2024 | Buy Now | 6.17% | BMO Capital | Evan Seigerman62% | $142 → $128 | Maintains | Market Perform | Get Alert |
08/29/2024 | Buy Now | 31.88% | Piper Sandler | David Amsellem75% | $131 → $159 | Upgrade | Neutral → Overweight | Get Alert |
08/29/2024 | Buy Now | 12.81% | RBC Capital | Brian Abrahams31% | $143 → $136 | Maintains | Sector Perform | Get Alert |
08/29/2024 | Buy Now | 57.6% | HC Wainwright & Co. | Andrew Fein54% | $190 → $190 | Reiterates | Buy → Buy | Get Alert |
08/29/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
08/19/2024 | Buy Now | 56.77% | Jefferies | Akash Tewari41% | $177 → $189 | Maintains | Buy | Get Alert |
08/07/2024 | Buy Now | 50.13% | JP Morgan | Anupam Rama55% | $173 → $181 | Maintains | Overweight | Get Alert |
08/05/2024 | Buy Now | 57.6% | HC Wainwright & Co. | Andrew Fein54% | $160 → $190 | Maintains | Buy | Get Alert |
08/02/2024 | Buy Now | 18.61% | RBC Capital | Brian Abrahams31% | $136 → $143 | Maintains | Sector Perform | Get Alert |
08/02/2024 | Buy Now | 49.3% | Guggenheim | Yatin Suneja47% | $170 → $180 | Maintains | Buy | Get Alert |
08/02/2024 | Buy Now | 31.06% | Citigroup | David Hoang68% | $150 → $158 | Maintains | Neutral | Get Alert |
08/02/2024 | Buy Now | 81.65% | Oppenheimer | Jay Olson60% | $216 → $219 | Maintains | Outperform | Get Alert |
08/02/2024 | Buy Now | 49.3% | Barclays | Carter Gould53% | $169 → $180 | Maintains | Overweight | Get Alert |
08/02/2024 | Buy Now | 49.3% | Baird | Brian Skorney57% | $157 → $180 | Maintains | Outperform | Get Alert |
08/01/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
07/25/2024 | Buy Now | 28.57% | Cantor Fitzgerald | Charles Duncan69% | $155 → $155 | Reiterates | Overweight → Overweight | Get Alert |
07/25/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
07/12/2024 | Buy Now | 41.01% | Morgan Stanley | Jeffrey Hung53% | $160 → $170 | Maintains | Overweight | Get Alert |
07/10/2024 | Buy Now | 43.5% | JP Morgan | Anupam Rama55% | $169 → $173 | Maintains | Overweight | Get Alert |
06/12/2024 | Buy Now | 32.71% | Morgan Stanley | Jeffrey Hung53% | $160 → $160 | Maintains | Overweight | Get Alert |
05/29/2024 | Buy Now | 26.08% | Wedbush | Laura Chico36% | $152 → $152 | Reiterates | Outperform → Outperform | Get Alert |
05/28/2024 | Buy Now | 60.09% | UBS | Ashwani Verma51% | $174 → $193 | Maintains | Buy | Get Alert |
05/14/2024 | Buy Now | 45.16% | Evercore ISI Group | Cory Kasimov68% | → $175 | Initiates | → Outperform | Get Alert |
05/03/2024 | Buy Now | 24.42% | Citigroup | David Hoang68% | $140 → $150 | Maintains | Neutral | Get Alert |
05/02/2024 | Buy Now | 36.03% | Canaccord Genuity | Sumant Kulkarni34% | $154 → $164 | Maintains | Buy | Get Alert |
05/02/2024 | Buy Now | 41.01% | Guggenheim | Yatin Suneja47% | $164 → $170 | Maintains | Buy | Get Alert |
05/02/2024 | Buy Now | 40.18% | Barclays | Carter Gould53% | $150 → $169 | Maintains | Overweight | Get Alert |
05/02/2024 | Buy Now | 14.47% | BMO Capital | Evan Seigerman62% | $129 → $138 | Maintains | Market Perform | Get Alert |
05/02/2024 | Buy Now | 79.16% | Oppenheimer | Jay Olson60% | $200 → $216 | Maintains | Outperform | Get Alert |
05/02/2024 | Buy Now | 32.71% | HC Wainwright & Co. | Andrew Fein54% | $150 → $160 | Maintains | Buy | Get Alert |
05/02/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
05/01/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
04/24/2024 | Buy Now | 24.42% | HC Wainwright & Co. | Andrew Fein54% | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
04/24/2024 | Buy Now | 41.01% | Wells Fargo | Mohit Bansal57% | $140 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
04/24/2024 | Buy Now | 65.89% | Oppenheimer | Jay Olson60% | $200 → $200 | Maintains | Outperform | Get Alert |
04/23/2024 | Buy Now | — | Needham | Ami Fadia53% | — | Reiterates | → Hold | Get Alert |
04/17/2024 | Buy Now | 21.93% | Wedbush | Laura Chico36% | $147 → $147 | Reiterates | Outperform → Outperform | Get Alert |
04/10/2024 | Buy Now | 28.57% | Cantor Fitzgerald | Charles Duncan69% | → $155 | Reiterates | Overweight → Overweight | Get Alert |
03/20/2024 | Buy Now | 31.06% | JP Morgan | Anupam Rama55% | $148 → $158 | Maintains | Overweight | Get Alert |
03/13/2024 | Buy Now | 65.89% | Oppenheimer | Jay Olson60% | $170 → $200 | Maintains | Outperform | Get Alert |
02/23/2024 | Buy Now | 22.76% | JP Morgan | Anupam Rama55% | $154 → $148 | Maintains | Overweight | Get Alert |
02/08/2024 | Buy Now | 16.12% | Citigroup | David Hoang68% | $141 → $140 | Maintains | Neutral | Get Alert |
02/08/2024 | Buy Now | 16.12% | Mizuho | Uy Ear39% | $116 → $140 | Maintains | Neutral | Get Alert |
02/08/2024 | Buy Now | 16.12% | Wells Fargo | Mohit Bansal57% | $127 → $140 | Maintains | Equal-Weight | Get Alert |
01/25/2024 | Buy Now | 26.91% | Goldman Sachs | Chris Shibutani45% | $134 → $153 | Maintains | Buy | Get Alert |
01/23/2024 | Buy Now | 24.42% | Barclays | Carter Gould53% | $145 → $150 | Maintains | Overweight | Get Alert |
12/18/2023 | Buy Now | 19.44% | Stifel | Paul Matteis5% | $141 → $144 | Maintains | Buy | Get Alert |
12/13/2023 | Buy Now | 5.34% | Wells Fargo | Mohit Bansal57% | $110 → $127 | Maintains | Equal-Weight | Get Alert |
12/13/2023 | Buy Now | 5.34% | Citigroup | David Hoang68% | → $127 | Initiates | → Neutral | Get Alert |
12/12/2023 | Buy Now | 12.81% | Deutsche Bank | Neena Bitritto-Garg61% | → $136 | Initiates | → Buy | Get Alert |
12/07/2023 | Buy Now | 24.42% | Canaccord Genuity | Sumant Kulkarni34% | → $150 | Reiterates | Buy → Buy | Get Alert |
11/10/2023 | Buy Now | -17.05% | BMO Capital | Evan Seigerman62% | $111 → $100 | Maintains | Market Perform | Get Alert |
11/10/2023 | Buy Now | 0.36% | RBC Capital | Brian Abrahams31% | $128 → $121 | Maintains | Sector Perform | Get Alert |
11/10/2023 | Buy Now | -5.44% | Mizuho | Uy Ear39% | $116 → $114 | Maintains | Neutral | Get Alert |
11/03/2023 | Buy Now | -3.78% | Mizuho | Uy Ear39% | $113 → $116 | Maintains | Neutral | Get Alert |
The latest price target for Neurocrine Biosciences (NASDAQ:NBIX) was reported by Piper Sandler on May 6, 2025. The analyst firm set a price target for $154.00 expecting NBIX to rise to within 12 months (a possible 27.74% upside). 67 analyst firms have reported ratings in the last year.
The latest analyst rating for Neurocrine Biosciences (NASDAQ:NBIX) was provided by Piper Sandler, and Neurocrine Biosciences reiterated their overweight rating.
The last upgrade for Neurocrine Biosciences Inc happened on April 15, 2025 when Needham raised their price target to $138. Needham previously had a hold for Neurocrine Biosciences Inc.
There is no last downgrade for Neurocrine Biosciences.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.
While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a reiterated with a price target of $160.00 to $154.00. The current price Neurocrine Biosciences (NBIX) is trading at is $120.56, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.